This section contains prescribing guidelines and information on:
- Acne (management from 12 years of age)
- Atopic Dermatitis
- Chronic Urticaria
- Eczema (children and adults)
- Hyperhidrosis
- Psoriasis
- Viral Warts
In addition please note SWL pathway relaxations for existing patients on JAK inhibitors, who require a switch to an alternative drug due to MHRA safety warning for Janus Kinase (JAK) Inhibitors.